Abstracts tagged "Lupus"

Abstract Number: 2330 • 2018 ACR/ARHP Annual Meeting
Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
Smarika Sapkota¹, Sara Baig², Toy Hess³, Ann Marie O'Connell⁴, Jeremiah Menk³, Parastoo Fazeli⁵ and Anna K. Shmagel⁶, ¹Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ²Department of Internal Medicine, University of Minnesota, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minnepolis, MN, ⁵Rheumatology, University of Minnesota, Minneapolis, MN, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose: Glucocorticoids(GC) are frequently used for the treatment of systemic lupus erythematosus (SLE), and glucocorticoid induced osteoporosis (GIOP) is a well-known complication of long term…
Abstract Number: 2946 • 2018 ACR/ARHP Annual Meeting
T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Deepak Rao¹, Alexandra Bocharnikov², Chamith Fonseka³, Joshua Keegan², Betty Diamond⁴, Jennifer Anolik⁵, Peter Nigrovic¹, Soumya Raychaudhuri^3,6, James A. Lederer⁷ and Michael Brenner⁸, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ⁷Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions and production of autoantibodies are hallmark features of SLE. T follicular helper (Tfh) cells are generally considered the principal…
Abstract Number: PP09 • 2018 ACR/ARHP Annual Meeting
Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
Marisa Zeppieri-Caruana, Lupus Chick, New York, NY
Background/Diagnosis: Like most people who live with a chronic illness and/or autoimmune disease, my story started long before I realized. Symptoms came and went throughout…
Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 972 • 2018 ACR/ARHP Annual Meeting
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Joan T. Merrill¹, Diane E. Shevell², Dominique Duchesne², Miroslawa Nowak², Sudeep Kundu², Ihab G. Girgis², Yanhua Sarah Hu², Steven G. Nadler³, Subhashis Banerjee² and John Throup², ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol-Myers Squibb, Princeton, NJ, ³Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The T cell costimulatory molecule, CD28, is critical for the activation of pathogenic T cells in autoimmune diseases.1,2 An anti-CD28 domain antagonist antibody, lulizumab…
Abstract Number: 1888 • 2018 ACR/ARHP Annual Meeting
SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
Eric Yen and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: Ten-year survival of SLE has improved from <50% in the 1950s to ~95% in the 2000s. However, the relative and true disease burden for…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 2959 • 2018 ACR/ARHP Annual Meeting
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Candace H. Feldman¹, Cameron Speyer¹, Rachel Ashby², Bonnie L. Bermas³, Shamik Bhattacharyya⁴, Eliza Chakravarty⁵, Brendan Everett⁶, Elizabeth Ferucci⁷, Aimee O. Hersh⁸, Francisco Marty⁹, Joseph F. Merola¹⁰, Rosalind Ramsey-Goldman¹¹, Brad Rovin¹², Mary Beth Son¹³, Laura Tarter¹⁴, Sushrut Waikar¹⁵, Jinoos Yazdany¹⁶, Joel Weissman¹⁷ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, UT Southwestern, Dallas, TX, ⁴Neurology, Brigham and Women's Hospital, Boston, MA, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Cardiology, Brigham and Women's Hospital, Boston, MA, ⁷Alaska Native Medical Center, Anchorage, AK, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Infectious Disease, Brigham and Women's Hospital, Boston, MA, ¹⁰Medicine, Rheumatology and Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Ohio State University Wexner Medical Center, Columbus, OH, ¹³Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Renal, Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, San Francisco, San Francisco, CA, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The U.S. Agency for Healthcare Research and Quality developed a set of general ambulatory care-sensitive conditions that may result acute care use (hospitalizations and…
Abstract Number: 18 • 2018 ACR/ARHP Annual Meeting
Cytoplasmic FOXO1 Identifies Novel Disease-Activity Associated B Cell Subsets in SLE
Molly Hritzo¹ and Amit Golding², ¹Microbiology and Molecular Immunology, University of Maryland School of Medicine, Baltimore, MD, ²10 South Pine Street, Baltimore VA/VAMHCS AND University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A key integrator of external stimuli in lymphocytes, Forkhead box protein O1 (FOXO1) is a highly attractive factor to study in SLE because it…
Abstract Number: 714 • 2018 ACR/ARHP Annual Meeting
A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín^1,2, Jiram Torres-Ruíz³, Nancy R Mejía-Domínguez⁴, Guillermo Juárez-Vega⁵, Javier Merayo-Chalico³, Ana Barrera-Vargas³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ⁴Bioinformatics, Biostatistics and Computational Biology Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁵Flow Cytometry Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have multiple innate and adaptive immune response abnormalities. It is unknown whether they play a key role in…
Abstract Number: 1003 • 2018 ACR/ARHP Annual Meeting
Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions
Sladjana Skopelja-Gardner¹, Xizhang Sun², Joyce Tai³, Lucrezia Colonna³, Lena Tanaka⁴ and Keith B. Elkon⁵, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Medicine/Rheumatology, University of Washington, Seattle, WA, ⁵University of Washington, Seattle, WA
Background/Purpose: Two-thirds of systemic lupus erythematosus (SLE) patients are sensitive to sunlight and artificial light. Ultraviolet (UV) B light induces sterile inflammation in the skin…
Abstract Number: 1897 • 2018 ACR/ARHP Annual Meeting
Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway
Andrea Fava¹, Yuji Zhang², Nir Hacohen³, Arnon Arazi⁴, Celine C. Berthier⁵, Deepak Rao⁶, Michael Brenner⁷, David Wofsy⁸, Anne Davidson⁹, Matthias Kretzler¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Betty Diamond¹³ and Michelle Petri¹⁴, ¹Departement of Medicine - Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ³Harvard Medical School, Boston, MA, ⁴Broad Institute, Cambridge, MA, ⁵Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁶Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Center for Autoimmunity, Musculoskeletal & Hematopoietic Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Division of Nephrology, University of Michigan, Ann Arbor, MI, ¹¹University of Cincinnati, Cincinnati, OH, ¹²University of Cincinnati College of Medicine, Cincinnati, OH, ¹³The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-American (AA) ethnicity is associated with a 3-fold higher risk of developing systemic lupus erythematosus (SLE). In addition, there is an increased risk of…
Abstract Number: 2437 • 2018 ACR/ARHP Annual Meeting
Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of fetal growth restriction and birth of small for gestational age (SGA) concepts. Fetuses…
Abstract Number: 91 • 2018 ACR/ARHP Annual Meeting
Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE
Antonios Psarras^1,2,3, Adewonuola Alase¹, Agne Antanaviciute⁴, Ian Carr⁴, Miriam Wittmann^1,2, George C Tsokos⁵, Paul Emery^1,6 and Edward M Vital^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, ⁴Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: SLE is characterized by persistently high type I IFN activity. Plasmacytoid dendritic cells (pDCs) produce large amounts of IFNs in viral infections in response…
Abstract Number: 716 • 2018 ACR/ARHP Annual Meeting
Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease
Clemence David¹, Gillian Divard¹, Rachid Abbas¹, Brigitte Escoubet¹, Marie-Paule Chauveheid¹, Diane Rouzaud¹, Anne Boutten¹, Thomas Papo¹, Monique Dehoux¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Our study aimed to determine whether sCD163, a soluble macrophage marker upregulated in numerous inflammatory disorders, might be predictive of accelerated atherosclerosis associated with…

« Previous Page
1
…
4
5
6
7
8
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].